> top > docs > PubMed:33152616 > annotations

PubMed:33152616 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-136 Sentence denotes Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
T2 137-315 Sentence denotes Coronavirus outbreak in December 2019 (COVID-19) is an emerging viral disease that poses major menace to Humans and it's a crucial need to find the possible treatment strategies.
T3 316-499 Sentence denotes Spike protein (S2), a envelop glycoprotein aids viral entry into the host cells that corresponds to immunogenic ACE2 receptor binding and represents a potential antiviral drug target.
T4 500-693 Sentence denotes Several drugs such as antimalarial, antibiotic, anti-inflammatory and HIV-protease inhibitors are currently undergoing treatment as clinical studies to test the efficacy and safety of COVID-19.
T5 694-788 Sentence denotes Some promising results have been observed with the patients and also with high mortality rate.
T6 789-870 Sentence denotes Hence, there is a need to screen the best CoV inhibitors using insilico analysis.
T7 871-1033 Sentence denotes The Molecular methodologies applied in the present study are, Molecular docking, virtual screening, drug-like and ADMET prediction helps to target CoV inhibitors.
T8 1034-1121 Sentence denotes The results were screened based on docking score, H-bonds, and amino acid interactions.
T9 1122-1690 Sentence denotes The results shows HIV-protease inhibitors such as cobicistat (-8.3kcal/mol), Darunavir (-7.4kcal/mol), Lopinavir (-9.1kcal/mol) and Ritonavir (-8.0 kcal/mol), anti-inflammatory drugs such as Baricitinib (-5.8kcal/mol), Ruxolitinib (-6.5kcal/mol), Thalidomide (-6.5kcal/mol), antibiotic drugs such as Erythromycin(-9.0kcal/mol) and Spiramycin (-8.5kcal/mol) molecules have good affinity towards spike protein compared to antimalarial drugs Chloroquine (-6.2kcal/mol), Hydroxychloroquine (-5.2kcal/mol) and Artemisinin (-6.8kcal/mol) have poor affinity to spike protein.
T10 1691-1814 Sentence denotes The insilico pharmacological evaluation shows that these molecules exhibit good affinity of drug-like and ADMET properties.
T11 1815-2044 Sentence denotes Hence, we propose that HIVprotease, anti-inflammatory and antibiotic inhibitors are the potential lead drug molecules for spike protein and preclinical studies needed to confirm the promising therapeutic ability against COVID-19.
T1 0-136 Sentence denotes Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
T2 137-315 Sentence denotes Coronavirus outbreak in December 2019 (COVID-19) is an emerging viral disease that poses major menace to Humans and it's a crucial need to find the possible treatment strategies.
T3 316-499 Sentence denotes Spike protein (S2), a envelop glycoprotein aids viral entry into the host cells that corresponds to immunogenic ACE2 receptor binding and represents a potential antiviral drug target.
T4 500-693 Sentence denotes Several drugs such as antimalarial, antibiotic, anti-inflammatory and HIV-protease inhibitors are currently undergoing treatment as clinical studies to test the efficacy and safety of COVID-19.
T5 694-788 Sentence denotes Some promising results have been observed with the patients and also with high mortality rate.
T6 789-870 Sentence denotes Hence, there is a need to screen the best CoV inhibitors using insilico analysis.
T7 871-1033 Sentence denotes The Molecular methodologies applied in the present study are, Molecular docking, virtual screening, drug-like and ADMET prediction helps to target CoV inhibitors.
T8 1034-1121 Sentence denotes The results were screened based on docking score, H-bonds, and amino acid interactions.
T9 1122-1690 Sentence denotes The results shows HIV-protease inhibitors such as cobicistat (-8.3kcal/mol), Darunavir (-7.4kcal/mol), Lopinavir (-9.1kcal/mol) and Ritonavir (-8.0 kcal/mol), anti-inflammatory drugs such as Baricitinib (-5.8kcal/mol), Ruxolitinib (-6.5kcal/mol), Thalidomide (-6.5kcal/mol), antibiotic drugs such as Erythromycin(-9.0kcal/mol) and Spiramycin (-8.5kcal/mol) molecules have good affinity towards spike protein compared to antimalarial drugs Chloroquine (-6.2kcal/mol), Hydroxychloroquine (-5.2kcal/mol) and Artemisinin (-6.8kcal/mol) have poor affinity to spike protein.
T10 1691-1814 Sentence denotes The insilico pharmacological evaluation shows that these molecules exhibit good affinity of drug-like and ADMET properties.
T11 1815-2044 Sentence denotes Hence, we propose that HIVprotease, anti-inflammatory and antibiotic inhibitors are the potential lead drug molecules for spike protein and preclinical studies needed to confirm the promising therapeutic ability against COVID-19.

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 70-73 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T2 108-120 Body_part denotes glycoprotein http://purl.org/sig/ont/fma/fma62925
T3 322-329 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T4 346-358 Body_part denotes glycoprotein http://purl.org/sig/ont/fma/fma62925
T5 390-395 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T6 570-573 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T7 1097-1107 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T8 1140-1143 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T9 1522-1529 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T10 1682-1689 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T11 1943-1950 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 176-184 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 201-214 Disease denotes viral disease http://purl.obolibrary.org/obo/MONDO_0005108
T3 684-692 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 2035-2043 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 242-248 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes Humans
T2 258-259 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 331-333 http://purl.obolibrary.org/obo/CLO_0008922 denotes S2
T4 331-333 http://purl.obolibrary.org/obo/CLO_0050052 denotes S2
T5 336-337 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T6 390-395 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T7 465-466 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T8 652-656 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T9 805-806 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 23-35 Chemical denotes antimalarial http://purl.obolibrary.org/obo/CHEBI_38068
T2 37-46 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T3 70-93 Chemical denotes HIV protease inhibitors http://purl.obolibrary.org/obo/CHEBI_35660
T4 74-93 Chemical denotes protease inhibitors http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258
T6 83-93 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T7 108-120 Chemical denotes glycoprotein http://purl.obolibrary.org/obo/CHEBI_17089
T8 322-329 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T9 331-333 Chemical denotes S2 http://purl.obolibrary.org/obo/CHEBI_29387
T10 346-358 Chemical denotes glycoprotein http://purl.obolibrary.org/obo/CHEBI_17089
T11 477-491 Chemical denotes antiviral drug http://purl.obolibrary.org/obo/CHEBI_36044
T12 477-486 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T13 487-491 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T14 508-513 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T15 522-534 Chemical denotes antimalarial http://purl.obolibrary.org/obo/CHEBI_38068
T16 536-546 Chemical denotes antibiotic http://purl.obolibrary.org/obo/CHEBI_33281
T17 570-593 Chemical denotes HIV-protease inhibitors http://purl.obolibrary.org/obo/CHEBI_35660
T18 574-593 Chemical denotes protease inhibitors http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258
T20 583-593 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T21 835-845 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T22 971-975 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T23 1022-1032 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T24 1097-1107 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T25 1097-1102 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T26 1103-1107 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T27 1140-1163 Chemical denotes HIV-protease inhibitors http://purl.obolibrary.org/obo/CHEBI_35660
T28 1144-1163 Chemical denotes protease inhibitors http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258
T30 1153-1163 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T31 1172-1182 Chemical denotes cobicistat http://purl.obolibrary.org/obo/CHEBI_72291
T32 1199-1208 Chemical denotes Darunavir http://purl.obolibrary.org/obo/CHEBI_367163
T33 1225-1234 Chemical denotes Lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T34 1281-1304 Chemical denotes anti-inflammatory drugs http://purl.obolibrary.org/obo/CHEBI_35472
T35 1299-1304 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T36 1369-1380 Chemical denotes Thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T37 1397-1407 Chemical denotes antibiotic http://purl.obolibrary.org/obo/CHEBI_33281
T38 1408-1413 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T39 1422-1434 Chemical denotes Erythromycin http://purl.obolibrary.org/obo/CHEBI_42355
T40 1453-1463 Chemical denotes Spiramycin http://purl.obolibrary.org/obo/CHEBI_85260
T41 1479-1488 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T42 1522-1529 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T43 1542-1554 Chemical denotes antimalarial http://purl.obolibrary.org/obo/CHEBI_38068
T44 1555-1560 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T45 1561-1572 Chemical denotes Chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T46 1682-1689 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T47 1748-1757 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T48 1783-1787 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T49 1873-1883 Chemical denotes antibiotic http://purl.obolibrary.org/obo/CHEBI_33281
T50 1884-1894 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T51 1918-1922 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T52 1923-1932 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T53 1943-1950 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 364-395 http://purl.obolibrary.org/obo/GO_0046718 denotes viral entry into the host cells
T2 370-389 http://purl.obolibrary.org/obo/GO_0044409 denotes entry into the host

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1 124-135 Species denotes coronavirus Tax:11118
13 137-148 Species denotes Coronavirus Tax:11118
14 176-184 Disease denotes COVID-19 MESH:C000657245
15 201-214 Disease denotes viral disease MESH:D001102
16 242-248 Species denotes Humans Tax:9606
17 684-692 Disease denotes COVID-19 MESH:C000657245
18 745-753 Species denotes patients Tax:9606
19 831-834 Species denotes CoV Tax:11118
20 985-990 Chemical denotes ADMET
21 1018-1021 Species denotes CoV Tax:11118
22 1225-1234 Chemical denotes Lopinavir MESH:D061466
23 2035-2043 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-136 Sentence denotes Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
T2 137-315 Sentence denotes Coronavirus outbreak in December 2019 (COVID-19) is an emerging viral disease that poses major menace to Humans and it's a crucial need to find the possible treatment strategies.
T3 316-499 Sentence denotes Spike protein (S2), a envelop glycoprotein aids viral entry into the host cells that corresponds to immunogenic ACE2 receptor binding and represents a potential antiviral drug target.
T4 500-693 Sentence denotes Several drugs such as antimalarial, antibiotic, anti-inflammatory and HIV-protease inhibitors are currently undergoing treatment as clinical studies to test the efficacy and safety of COVID-19.
T5 694-788 Sentence denotes Some promising results have been observed with the patients and also with high mortality rate.
T6 789-870 Sentence denotes Hence, there is a need to screen the best CoV inhibitors using insilico analysis.
T7 871-1033 Sentence denotes The Molecular methodologies applied in the present study are, Molecular docking, virtual screening, drug-like and ADMET prediction helps to target CoV inhibitors.
T8 1034-1121 Sentence denotes The results were screened based on docking score, H-bonds, and amino acid interactions.
T9 1122-1690 Sentence denotes The results shows HIV-protease inhibitors such as cobicistat (-8.3kcal/mol), Darunavir (-7.4kcal/mol), Lopinavir (-9.1kcal/mol) and Ritonavir (-8.0 kcal/mol), anti-inflammatory drugs such as Baricitinib (-5.8kcal/mol), Ruxolitinib (-6.5kcal/mol), Thalidomide (-6.5kcal/mol), antibiotic drugs such as Erythromycin(-9.0kcal/mol) and Spiramycin (-8.5kcal/mol) molecules have good affinity towards spike protein compared to antimalarial drugs Chloroquine (-6.2kcal/mol), Hydroxychloroquine (-5.2kcal/mol) and Artemisinin (-6.8kcal/mol) have poor affinity to spike protein.
T10 1691-1814 Sentence denotes The insilico pharmacological evaluation shows that these molecules exhibit good affinity of drug-like and ADMET properties.
T11 1815-2044 Sentence denotes Hence, we propose that HIVprotease, anti-inflammatory and antibiotic inhibitors are the potential lead drug molecules for spike protein and preclinical studies needed to confirm the promising therapeutic ability against COVID-19.